Anti rabies immunoglobulin
CN β US| HS Code | Tariff Rate | Origin | Destination | Doc |
|---|---|---|---|---|
| 3002120010 | 10.0% | CN | US | Official Doc |
| 3002120030 | 10.0% | CN | US | Official Doc |
AI Analysis
𧬠Anti-Rabies Immunoglobulin (ARIG) β Human Immune Serum Globulin
π HS Code Reference & Customs Clearance Guide | 2026 Latest Tariff Analysis | Professional Bio-Therapeutic Clearance Strategy
π 1. Product Definition & Classification: Do You Truly Understand "Anti-Rabies Immunoglobulin"?
Anti-Rabies Immunoglobulin (ARIG) is a critical biological product used for post-exposure prophylaxis (PEP) against rabies. It is a concentrated preparation of human antibodies specifically targeting the rabies virus.
In international trade, this product falls under Chapter 30: Pharmaceutical Products, specifically within the category of immunological products. It is distinct from vaccines (which stimulate active immunity) as it provides passive immunity through the direct administration of pre-formed antibodies.
β οΈ Key Distinction:
- Vaccines (e.g., Rabies Vaccine): Stimulate the bodyβs own immune system to produce antibodies. HS Code typically3002.20.
- Immunoglobulins/Serum (e.g., Anti-Rabies Immunoglobulin): Provide immediate, passive protection by injecting antibodies directly. This is the classification for the input product.
- Blood Fractions: ARIG is often classified alongside "human blood fractions" because it is derived from human plasma.
π¦ 2. HS Code Classification Details (2026 Latest Tariff Authority)
Based on the provided data, Anti-Rabies Immunoglobulin is classified under HS Code 3002.12.00.30 as "Human immune blood sera".
| HS Code | Product Description | Classification Logic | Tax Rate |
|---|---|---|---|
3002.12.00.30 |
Human immune blood sera | Anti-Rabies Immunoglobulin is a specific immunoglobulin derived from human plasma. It fits the definition of "immune sera" or "blood fractions" prepared for therapeutic/prophylactic use. | 0.0% |
3002.12.00.10 |
Human blood plasma | Not applicable. This code is for raw plasma, not the purified immunoglobulin product. | 0.0% |
π Critical Note:
- Anti-Rabies Immunoglobulin is NOT classified as "Human blood" (raw) but as a processed immunological product.
- The specific sub-heading3002.12.00.30explicitly covers immune sera, which includes antibodies against specific pathogens like rabies.
- Do not misclassify as3002.20(Vaccines) β the tax rate may differ, and regulatory requirements for biologicals vs. vaccines are distinct.
π° 3. 2026 Latest Tariff Rate Breakdown (Detailed Tax Clause)
β Applicable Country: United States (US)
β Origin: China (CN) (Assumed based on standard trade context; verify origin for specific duty)
β Effective Time: 2026 Current Tariff Schedule
π― 1. 3002.12.00.30 β Human Immune Blood Sera (Anti-Rabies Immunoglobulin)
| Item | Content |
|---|---|
| Base Tariff Rate | 0.0% (ad valorem) |
| Additional Tariffs | 0.0% (No Section 301 or IEEPA duties apply to this specific biological class in the provided data) |
| Total Effective Tax Rate | 0.0% |
| Tax Calculation | CIF Value Γ 0% = $0 |
| De Minimis Eligibility | β Not Applicable (High-value biologicals rarely qualify for de minimis; strict customs oversight applies) |
| Legal Basis | USITC:3002.12.00.30 β FOOTNOTE:Biological Products |
π Interpretation:
- Zero Duty Advantage: Human immune sera and specific immunoglobulins often enjoy zero tariff rates under US Harmonized Tariff Schedule (HTS) to facilitate public health security and rapid response to infectious diseases.
- No Section 301 Impact: Unlike many manufactured goods, therapeutic blood fractions and immune sera are generally exempt from the 25% Section 301 tariffs and the 10% IEEPA additional duties mentioned in other categories.
- However: Non-tariff barriers are significant (see below).
π οΈ 4. Customs Clearance Practical Advice (Operational Pitfalls Guide)
β 1. Documentation Checklist (Non-Negotiable)
| Document | Required | Explanation |
|---|---|---|
| β FDA Prior Notice | βοΈ Mandatory | Biological products require prior notice to FDA before arrival in the US. |
| β Lot Release Certificate | βοΈ Mandatory | Each batch must have a certificate of analysis (CoA) from the manufacturer. |
| β Establishment Registration | βοΈ Mandatory | The foreign manufacturer must be registered with FDA (21 CFR Part 607). |
| β Clinical Trial Data (if applicable) | βοΈ If new | For investigational uses, IND (Investigational New Drug) number required. |
| β Commercial Invoice | βοΈ | Must clearly state: "Anti-Rabies Immunoglobulin, Human Source, For Therapeutic Use." |
| β Cold Chain Records | βοΈ Critical | Temperature logs (2β8Β°C) for the entire supply chain. |
| β Country of Origin Certificate | βοΈ | To prove eligibility for 0% duty. |
β 2. Declaration Tips (Key Mnemonic)
π₯ βBio-Identity, Cold Chain, FDA First, Zero Duty but Strict Review!β
| Scenario | Correct Declaration | Wrong Practice |
|---|---|---|
| Anti-Rabies Immunoglobulin | 3002.12.00.30 β "Human Immune Sera" |
Misclassified as 3002.20 (Vaccine) β Regulatory Conflict |
| Raw Human Plasma | 3002.12.00.10 β "Human Blood Plasma" |
Misclassified as finished immunoglobulin β Value Discrepancy |
| Vaccine + Immunoglobulin Kit | Split Declaration | Combine into one line item β Customs Rejection |
| Non-Cold Chain Delivery | Refuse Shipment | Accept without temp logs β FDA Detention & Destruction |
β 3. Special Handling Cases
| Case | Handling Advice |
|---|---|
| Personal Import (Emergency) | β Prohibited. Human immune sera cannot be imported for personal use without FDA approval. |
| Hospital/Healthcare Import | β Standard. Requires hospital license and FDA facility registration. |
| Sample for Testing | β Allowed with FDA Form 348b and limited quantity. |
| Transit Through US | β Allowed if not entering US commerce; strict documentation still required. |
π 5. Global Market Comparison (2026 Latest)
| Country/Region | Recommended HS Code | Tariff | Regulatory Authority | Remarks |
|---|---|---|---|---|
| πΊπΈ USA | 3002.12.00.30 |
0.0% | FDA (CDER) | Zero duty, but strict FDA enforcement. |
| π¨π³ China | 3002.12.00.30 |
0.0% | NMPA | Zero duty; requires NMPA import license. |
| πͺπΊ EU | 3002.12.00 |
0.0% | EMA | Zero duty; requires EMA marketing authorization. |
| π¬π§ UK | 3002.12.00 |
0.0% | MHRA | Zero duty; post-Brexit rules align with EU closely. |
π Conclusion:
- Global Consensus: Most developed markets apply 0% tariffs to human immune sera to ensure access to life-saving therapies.
- Primary Barrier: Regulatory, not Tariff. FDA, EMA, and NMPA approvals are the main hurdles, not customs duties.
π 6. Common Errors & Pitfalls (Lessons Learned)
β Error 1: Classifying as 3002.20 (Vaccines)
π Consequence: FDA may reject shipment because regulatory pathways for vaccines vs. immunoglobulins differ.
π Result: Delay + $10,000+ in storage/repatriation costs.
β Error 2: Omitting "Human Source" in Description
π Consequence: Customs may suspect animal-derived product (different biosecurity rules).
π Result: Quarantine hold.
β Error 3: Ignoring Cold Chain Documentation
π Consequence: FDA will detain the shipment if temperature excursions are detected.
π Result: Product destruction.
β Error 4: Assuming De Minimis Applies
π Consequence: Biologicals are excluded from de minimis entry.
π Result: Full customs entry required, even for small samples.
β Correct Declaration Example:
"Anti-Rabies Immunoglobulin, Human Source, Liquid, For Therapeutic Use Only, Cold Chain Maintained, FDA Prior Notice Filed, HTS 3002.12.00.30"
π― 7. Conclusion: Precision in Bio-Trade is Non-Negotiable
π― Remember:
πΉ "Zero Duty is Sweet, But FDA is the Gatekeeper."
πΉ "HS 3002.12.00.30 for Immune Sera, 3002.20 for Vaccines β Don't Mix Them."
πΉ "Cold Chain + FDA Notice = Smooth Clearance."
π Pro Tip:
- Always file FDA Prior Notice at least 2 hours before arrival (by vessel) or 4 hours before arrival (by air).
- Ensure the manufacturerβs FDA Establishment ID is on the invoice.
- Verify lot release for every shipment; no exceptions.
π£ Immediate Action:
π Engage a FDA-licensed customs broker experienced in biologics.
π Prepare Cold Chain Logs and CoA (Certificate of Analysis) in advance.
π Secure FDA Prior Notice confirmation before shipment departure.
β¨ Professional Clearance Starts with Accurate Classification!
πΌ Your Life-Saving Product Deserves Zero Duty and Zero Delay!
Customer Reviews
About HS Code Classification
The Harmonized System (HS) is an internationally standardized nomenclature developed by the World Customs Organization (WCO) to classify traded products. Over 200 countries use the HS system as the basis for customs tariffs, trade statistics, and import/export regulations.
Each HS code follows a hierarchical structure:
- Chapter (2 digits) β Broad category of goods (e.g., Chapter 84: Machinery and Mechanical Appliances)
- Heading (4 digits) β More specific grouping within the chapter
- Subheading (6 digits) β Internationally standardized breakdown, used by all WCO member countries
- National subdivisions (8-10 digits) β Country-specific extensions for further classification, such as US HTSUS 10-digit codes
Correct HS code classification is essential for smooth customs clearance, accurate duty payment, and compliance with trade regulations. Misclassification can lead to customs delays, overpayment of duties, or penalties.
When importing from CN to US, the applicable tariff rates may include:
- Most-Favored-Nation (MFN) rate β The standard duty rate applied to WTO members
- General rate β Applied to countries without trade agreements
- Trade remedy duties β Additional tariffs such as Section 301 (anti-dumping), Section 232 (national security), or countervailing duties
The information provided on this page is for reference purposes only. For official classification, please consult with your local customs authority or a licensed customs broker.